EU/3/13/1152

About

Please note that this product was withdrawn from the Community register of designated orphan medicinal products in September 2017 on request of the sponsor.

On 17 July 2013, orphan designation (EU/3/13/1152) was granted by the European Commission to Merck KGaA, Germany, for (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl)diamidophosphate (also known as TH-302) for the treatment of pancreatic cancer.

The sponsorship was transferred to Chiltern International Limited, United Kingdom, in June 2016.

Key facts

Active substance
(1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl)diamidophosphate
Disease / condition
Treatment of pancreatic cancer
Date of decision
17/07/2013
Outcome
Withdrawn
Orphan decision number
EU/3/13/1152

Review of designation

Please note that this product was withdrawn from the Community register of designated orphan medicinal products in September 2017 on request of the sponsor.

Sponsor's contact details

Chiltern International Limited
171 Bath Road
Slough
Berkshire SL1 4AA
Tel. +44 (0)1315 507 700
http://www.chiltern.com/contact-us/

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating